I agree but also hope Gilead is smart enough to dig deep into how PS Targeting not only helps solid tumors along with blood disorders, but Neuroscience they can branch into.
Gilead's CART cell program can expand with PS Targeting and if they only see the other patents surrounding GLYT1 and how memory may also be a driving force in a deal especially when others are already in beginning stages with building patents ...but those patents may be questioned in how they discovered certain facts, unless PS Targeting was involved and we don't see it publicly, yet.